Dr. Sergei Kozlov – Laboratory Manager
Dr Sergei Koslov was awarded PhD from Department of Surgery, Faculty of Medicine, University of Queensland in 2000.The focus of his study was human genetic disorder ataxia-telangiectasia (A-T), the functional activities of ATM (A-T, mutated) protein kinase, ATM interacting partners and signalling pathways. The results of his research contributed significantly to seminal publications in top-ranking journals (Nature, Proc. Nat. Acad. Sci USA, Nature Genetics) in the field of DNA damage and ATM signalling and provided the foundation for future development of molecular diagnostics for A-T. During his entire research career, Sergei worked in the domain of human disease, specifically in the fields of hereditary ataxias, inflammation, breast and brain cancers, radiation therapy. He had been successfully involved in several research grants (ARC and NHMRC). In 2009, he was supported by the Australian Academy of Science “Scientific Visits to Europe” grant to work in GSI Helmholtzzentrum fur Schwerionenforschung GmbH, Darmstadt, a leading German experimental physics facility.
Through collaboration with Abteilung Biophysik, he applied, for the first time, heavy ion-beam microscopy to study ATM activation in DNA damage response (Kozlov et al, 2010). Dr Kozlov had a long-standing collaboration with Dr Mark Graham (CMRI, Sydney) in the field of quantitative mass spectrometry and phosphoprotein analysis.
He was the editor for a book entitled “ATM kinase” for the series “Methods in Molecular Biology” (Springer, 2017). As a Senior Medical Scientist (visiting) at the Medical Genetics laboratory (Pathology Queensland, RBWH) Dr Kozlov worked on a translational research project to develop a new strategy for mutation screening of genes relevant to renal diseases (Kozlov et al, Nephrology, 2012).
During his postdoctoral career working in QIMR and UQCCR, he has always supervised and mentored postgraduate students in collaborative projects (UQ, AIBN and GU), which resulted in publication of the first studies of stem cells in A-T. As an adjunct lecturer at the School of Medicine, UQ, and a Senior lecturer at the Griffith University Medical Research College, he participated in educational activities as an invited speaker.
In addition to student supervision, as a member of the Higher Degrees Committee (HDC) at QIMR for 9 years, Dr Kozlov reviewed and evaluated multiple Masters and PhD projects. Dr Kozlov completed a Graduate Certificate in Higher Education program at UQ (2016) where his major educational project for the course was focused on the development of innovative approaches to teaching of cell biology to international students. During his research career Dr Kozlov have engaged and successfully worked with many groups in diverse academic, clinical and inter-disciplinary environments. He joined Layton Vision Foundation in 2021 as a lab manager and research scientist to work on gene therapy projects.
Researcher ID URL: https://publons.com/researcher/2481045/sergei-kozlov/
Dr. Jason Steel – Director of Scientific Research
Dr Jason Steel is an expert in Molecular Biology and Immunology having trained and worked at the National Institutes of Health, USA, in the Cancer Gene Therapy Laboratory of Professor John C. Morris and the Cytokine Immunology and Immunotherapy laboratory of Distinguished Investigator Professor Thomas A. Waldmann. While at the NIH, Dr Steel was awarded the prestigious NIH Fellows Award for Research
Excellence (FARE) on 3 separate occasions for his work on gene therapy.
He has also led several gene therapy research teams including at the University of Cincinnati College of Medicine and The University of Queensland Faculty of Medicine before teaming up with Professor Chris Layton (Director of the LVF Ophthalmology Research Centre) to found Ocugene. In addition to his role at LVF, Dr Jason C. Steel is currently a Senior Lecturer and Biotechnology discipline lead at Central Queensland University, an Honorary Research Fellow in the Faculty of Medicine at the
University of Queensland and continues to work on targeted gene therapy using adenoviral and adeno-associated viruses as delivery vectors.
Dr. Brenda Castro – Scientific Fellow
Dr Castro is a pharmacist and obtained her Masters and Ph.D. degree in Pharmaceutical Sciences at Federal University of Minas Gerais (UFMG), in Brazil. Brenda is passionate about discovering and improving therapies for eye diseases and has been working within this field for over 8 years. During her Masters and PhD she studied the application of nanoparticles, implants, and peptides for different ocular diseases, especially uveitis.
In 2018, Brenda spent a year of her Ph.D. at the University of California, Irvine on a collaboration project developing and testing viral and nonviral nanoparticles for gene therapy. After completing her Ph.D., she moved to Australia in 2021 and started working at the Layton Vision Foundation as a postdoctoral Scientist.
Brenda’s work and collaborations have resulted in 10 publications in international journals and 3 patents.
Brendon Luke – Communications & Fundraising
Brendon is a marketing and communications professional with over a decade of experience working in the media industry with a strong passion for the Health Sector. He has personal experience from working as a phlebotomist with his Cert III in pathology and has worked within Clinic Centre’s, nursing homes & hospitals. He has nothing but admiration for the essential work undertaken to support the terminally ill and those in need of assistance and their loved ones.
With a Bachelor of Media Degree from the University of Macquarie he has become particularly passionate about research, fundraising and marketing in the non-for-profit health sector. Brendon is the head of our Marketing, Communications & Fundraising team at The Layton Foundation. He has come on board in early 2022 and is roaring to make a big impact within this space throughout the year.